Drug Trial Radar · NCT07798375
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
244
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Everest Medicines (China) Co.,Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Visara, Inc.
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)
Conditions
- Neovascular Age Related Macular Degeneration(nAMD)
Interventions
VIS-101 6.0mg Low concentrationBiological
VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
VIS-101 6.0mg High concentrationBiological
VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
VIS-101 9.0mg High concentrationBiological
VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
Aflibercept (Eylea)Biological
Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in BCVA from baseline to Week 36Time frame: From Baseline through Week 36
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.